| Name | Title | Contact Details |
|---|
Real-Time Radiography is a Pleasanton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medicorp Inc is a Mont-Royal, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
AgaMatrix is revolutionizing health care. We`ve sold over a million devices, two billion sensors, and we are the first FDA cleared medical device/app that works with iOS. AgaMatrix is an inventor and leader in consumer healthcare technology. With fewer than 150 people, almost 50% in R&D, we develop glucose monitoring and management systems for diabetes. Diabetes related care accounts for 20% of all healthcare spending in the US. Our innovative multidisciplinary technology vision includes iPhone, Android, and web applications supported by a cloud-based, Java back end for data management and exchange between patients and their doctors. Our UI/UX won the prestigious red dot design award. Our proprietary tech platform, protected by 126 granted/pending patents, uses DSP algorithms to double accuracy while reducing cost by 50%. AgaMatrix not only developed the first FDA cleared medical device that connects to an iPhone, but has over a dozen other FDA cleared products, and has sold over 2.5M meters and 3B biosensors. Our products are available in 20,000 retail locations and a worldwide in partnership with Sanofi, the world's largest pharmaceutical company. We`ve been featured by the New York Times and Fast Company, and we work with the world`s largest retailers (Walmart, Kroger, Target) and pharmaceutical companies (Sanofi, Perrigo) to change the way diabetes is treated.
SuperCare Medical is a City Of Industry, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.